ALS
New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial
Eloise McLennan
ALS, Biogen, clinical trials, Ionis Pharmaceuticals, pharma
0 Comment
Blow to Biogen as ALS hope tofersen flunks phase 3 trial
Phil Taylor
ALS, Biogen, neurodegenerative disease, tofersen
0 Comment
Digital/ R&D/ Video/ Views & Analysis/ Views & Analysis/ Views and analysis
Health Innovators: Teresa Arroyo-Gallego, nQ Medical
Paul Tunnah
ALS, Alzheimer's, artificial intelligence, digital health, health innovators, nQ Medical, Parkinson's
0 Comment
R&D/ Views & Analysis/ Views and analysis
Tackling diabetes & ALS with cell therapy
Catherine Longworth
ALS, cell therapy, Diabetes, Kadimastem
0 Comment
Digital/ News/ News/ Top stories
BMS joins forces with insitro to develop neurodegenerative treatments
Catherine Longworth
AI, ALS, Bristol-Myers Squibb, drug discovery, FTD, Insitro, machine learning
0 Comment
Partner content/ Partner Content/ Press releases
The ALS patient journey
sophie.berger@bluelatitude.com
ALS, ALSAwareness, EndALS, motor neuron disease, Rare diseases
0 Comment
Market Access/ News/ News/ Top stories
Mitsubishi Tanabe pulls ALS drug from EMA assessment
George Underwood
ALS, ema, Mitsubishi Tanabe, Radicava
0 Comment
Digital and Social Media/ News/ R&D
AI-discovered candidates show promise in ALS
Marco Ricci
AI, ALS, artificial intelligence, BenevolentAI, motor neurone disease
0 Comment
Candidates slow down motor neurone death in patient samples.